Bifiasthm(R)
Products
Information
Bifiasthm is a probiotic product proposed for children with asthma, in order to prevent asthmatic crises and support the balance of the immune system reactivitity. Bifiasthm is based on B. breve B632 and L. salivarius LS01, two strains with immunomodulatory activity targeted for allergic asthmatic subjects. A placebo-controlled clinical trial pending publication in 2020 and involving 500 asthmatic children showed that Bifiasthm was able to reduce significantly the episodes of asthma.
Distribution Areas
OceaniaNorth America (USA, Canada)AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied From
Italy
All categories
ProbioticsFinished Dosage FormsNatural ExtractsFunctional Food And Nutraceutical IngredientsAPIs (Active Pharmaceutical Ingredients)Innovative APIsProducts
Main Categories
Finished Dosage FormsNatural ExtractsAPIs (Active Pharmaceutical Ingredients)
